{"url_path":"/sec/mira/8-k/2026-06-25/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-25","source_url":"https://www.sec.gov/Archives/edgar/data/1904286/0001493152-26-030033-index.html","accession_number":"0001493152-26-030033","cik":"0001904286","ticker":"MIRA","issuer_name":"MIRA PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1904286/0001493152-26-030033-index.html","primary_entity_key":"0001904286","primary_entity_name":"MIRA PHARMACEUTICALS, INC."},"word_count":296,"has_tables":true,"body_markdown":"**Item\n7.01 Regulation FD Disclosure.**\n\n \n\nOn\nJune 25, 2026, MIRA Pharmaceuticals, Inc. (the “Company”) issued a press release reporting new preclinical data demonstrating\nMira-55’s differentiated mechanism of action and anxiolytic activity relative to THC. Mira-55 is the Company’s cannabinoid\nanalog in development for chronic inflammatory pain, designed to act on the same cannabinoid receptors as compounds found in cannabis,\nincluding THC, without carrying THC’s known liabilities, such as psychoactivity, and central nervous system side effects.\n\n \n\nUsing\nstandard preclinical models that researchers use to characterize THC-like compounds, the data showed that Mira-55 did not produce the\nlocomotor suppression or catalepsy associated with THC. Mira-55 produced a modest reduction in body temperature, but unlike the corresponding\nTHC effect, this was not reversed by rimonabant, a CB1 receptor antagonist, suggesting a mechanism distinct from classical CB1 agonism.\nIn a separate assay, Mira-55 demonstrated anxiolytic activity, in contrast to anxiogenic activity observed with rimonabant.\n\n \n\nThe\nCompany believes these findings, together with preclinical data reported in March 2026, support a pharmacological profile for Mira-55\nthat is differentiated from THC. These findings are based on preclinical pharmacology studies, and additional research will be required\nto further characterize Mira-55’s receptor-level activity as the Company advances its IND-enabling program. A copy of the press\nrelease is attached hereto as Exhibit 99.1 and incorporated herein by reference.\n\n \n\nThe\ninformation in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of\nSection 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities\nof that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the\nExchange Act, except as expressly set forth by specific reference in such filing."}